Form 4 for XLO Xilio Therapeutics, Inc.

Accepted 2021-10-28 00:00:00 ET · period of report 2021-10-26 · accession 0000318989-21-000078 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2021-10-28	2021-10-26	XLO	FIL Ltd	See Remark 1	C - Cnv Deriv	—	+218.7K	218.7K	New	—
DI	2021-10-28	2021-10-26	XLO	FIL Ltd	See Remark 1	C - Cnv Deriv	—	-2.08M	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-26	C	A	218,705	—	218,705	I Eight Roads Investments	—	—	(F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
2	Derivative	Series B Preferred Stock	2021-10-26	C	D	2,077,698	—	0	I Eight Roads Investments	— · — to —	218,705 Common Stock	(F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.